Financial Report: Abbott

Abbott

4Q Revenues: $7.2 billion (+16%)

4Q Earnings: $1.2 billion (loss of $476 million 4Q06)*

FY Revenues: $25.9 billion (+15%)

FY Earnings: $3.6 billion (+110%)

Comments: Worldwide pharmaceutical sales in the quarter were $4.2 billion, up 19%. U.S. pharma sales increased 17% and international sales were up 21%, driven by Humira, Kaletra and TriCor, as well as Niaspan sales of $179 million. Humira sales in 4Q07 and FY07 were $954 million (+54%) and $3 billion (+50%), respectively. 4Q07 and FY07 Kaletra sales were $371 million (+25%) and $1.3 billion (+17%), respectively. Tricor sales were up 20% to $392 million in the quarter and up 16% for the year to $1.2 billion. R&D expenses were $662 million in the quarter (+11%) and $2.5 billion for the year (+11%).

*4Q2006 earnings exclude after-tax charges of $1.3 billion for acquired in-process and collaborations R&D primarily related to the Kos acquisition.